Alpha Cognition (NASDAQ:ACOG) Inc (NASDAQ: ACOG) is a clinical-stage pharmaceutical company focused on the discovery and development of therapies aimed at improving memory and cognitive function in patients with neurological conditions. Leveraging advances in neuropharmacology, the company is developing bespoke compounds that target key pathways implicated in age-related memory loss, Alzheimer’s disease and other forms of dementia.
The lead product candidate, ALPHA-1062, is an investigational extended-release prodrug of a well-established cholinesterase inhibitor. Designed to provide a smoother pharmacokinetic profile and improved tolerability compared with immediate-release formulations, ALPHA-1062 is currently advancing through clinical trials to evaluate its safety, tolerability and cognitive effects in both healthy volunteers and patient populations. In addition, Alpha Cognition’s preclinical pipeline includes novel small molecules that modulate synaptic plasticity and neuroinflammation, with the goal of addressing underlying disease mechanisms.
Founded to translate cutting-edge neuroscience research into practical treatments, Alpha Cognition is headquartered in Westport, Connecticut. The company maintains research collaborations with leading academic institutions and contract research organizations across North America and Europe, positioning its programs for global clinical development and potential commercialization. By combining in-house discovery capabilities with external partnerships, Alpha Cognition seeks to streamline the path from early research through late-stage trials.
Alpha Cognition’s executive leadership team comprises seasoned industry professionals with extensive backgrounds in drug discovery, clinical development and regulatory affairs. The management team is supported by a board of directors and scientific advisory board that includes experts in neurology, pharmacology and translational medicine. Together, they are working to advance new therapeutic options for patients suffering from memory disorders and cognitive decline.
